Drugs Made in America AcquisDMAA
13F holders, Q2 2025 (June 30)32holders +8
10new positions
2sold out
1famous investor
$10.20avg. 13F price*
At the end of Q2 2025, 32 institutions reported holding Drugs Made in America Acquis (DMAA) in their 13F filings, up 8 from Q1 2025. 10 opened new positions and 2 sold out. The largest holders were Karpus Management, Inc. ($28.0M), First Trust Capital Management L.P. ($22.9M) and Polar Asset Management Partners Inc. ($19.4M). One famous investor held it David E. Shaw (0.0% of D. E. Shaw & Co.'s portfolio).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2847J104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $25.3M |
| Exits | 2 | $7.8M |
All 13F filers, Q1 2025 → Q2 2025: 4,203,217 shares bought and 3,444,949 shares sold, net +758,268 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 32 holders
| Karpus Management, Inc. | 0.90% | Add +18.1% | 2,744,109 | $28.0M |
| First Trust Capital Management L.P. | 1.55% | Add +8.5% | 2,242,500 | $22.9M |
| Polar Asset Management Partners Inc. | 0.65% | No change | 1,900,000 | $19.4M |
| Glazer Capital, LLC | 0.77% | Reduce -0.0% | 1,822,450 | $18.6M |
| Hudson Bay Capital Management LP | 0.14% | No change | 1,800,000 | $18.4M |
| Westchester Capital Management, LLC | 1.00% | Add +70.5% | 1,669,000 | $17.0M |
| Wolverine Asset Management LLC | 0.75% | Add +69.5% | 1,021,906 | $10.4M |
| Mizuho Securities USA LLC | 0.20% | — | 919,787 | $9.3M |
| Aristeia Capital, L.L.C. | 0.45% | Reduce -2.0% | 881,716 | $9.0M |
| D. E. Shaw & Co. | 0.01% | New | 690,000 | $7.0M |
| Heights Capital Management, Inc. | 2.14% | New | 650,000 | $6.6M |
| Atw Spac Management LLC | 9.26% | No change | 570,000 | $5.8M |
| Boothbay Fund Management, LLC | 0.18% | New | 570,000 | $5.8M |
| LMR Partners LLP | 0.12% | No change | 500,000 | $5.1M |
| Toronto Dominion Bank | 0.01% | Reduce -77.4% | 500,000 | $5.1M |
| Whitebox Advisors LLC | 0.29% | No change | 400,000 | $4.1M |
| AQR Arbitrage LLC | 0.14% | Reduce -1.1% | 376,314 | $3.8M |
| Mangrove Partners Im, LLC | 0.39% | No change | 350,000 | $3.6M |
| DLD Asset Management, LP | 0.93% | Reduce -46.1% | 188,722 | $1.9M |
| Schonfeld Strategic Advisors LLC | 0.01% | Reduce -25.4% | 149,215 | $1.5M |
| Radcliffe Capital Management, L.P. | 0.59% | New | 126,722 | $1.3M |
| Goldman Sachs Group Inc. | 0.00% | No change | 119,686 | $1.2M |
| Clear Street LLC | 0.01% | New | 112,615 | $1.1M |
| Shaolin Capital Management LLC | 0.27% | New | 100,000 | $1.0M |
| Verition Fund Management LLC | 0.01% | New | 100,000 | $1.0M |
| Warberg Asset Management LLC | 3.99% | No change | 92,055 | $939K |
| Bulldog Investors, LLP | 0.19% | New | 72,964 | $744K |
| Logan Stone Capital, LLC | 0.29% | New | 60,991 | $622K |
| Virtu Financial LLC | 0.02% | Add +46.9% | 46,685 | $476K |
| Geode Capital Management, LLC | 0.00% | Add +0.4% | 45,648 | $466K |
| Morgan Stanley | 0.00% | Add +445.0% | 109 | $1K |
| UBS Group AG | 0.00% | New | 1 | $10 |
"% of holder's portfolio" is DMAA's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.